Your browser doesn't support javascript.
loading
Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients.
Romo-Vaquero, María; Fernández-Villalba, Emiliano; Gil-Martinez, Ana-Luisa; Cuenca-Bermejo, Lorena; Espín, Juan Carlos; Herrero, María Trinidad; Selma, María Victoria.
Afiliación
  • Romo-Vaquero M; Laboratory of Food & Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia 30100, Spain. mvselma@cebas.csic.es.
  • Fernández-Villalba E; Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.
  • Gil-Martinez AL; Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain. mtherrer@um.es.
  • Cuenca-Bermejo L; Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.
  • Espín JC; Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain. mtherrer@um.es.
  • Herrero MT; Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.
  • Selma MV; Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain. mtherrer@um.es.
Food Funct ; 13(11): 6306-6316, 2022 Jun 06.
Article en En | MEDLINE | ID: mdl-35611932
Gut microbiota alteration (gut dysbiosis) occurs during the onset and progression of Parkinson's disease. Gut dysbiosis biomarkers could be relevant to prodromal disease. Urolithins, anti-inflammatory metabolites produced from some dietary polyphenols by specific gut microbial ecologies (urolithin metabotypes), have been proposed as biomarkers of gut microbiota composition and functionality. However, this has not been explored in Parkinson's disease patients. The current study aimed to assess associations between urolithin metabotypes, gut dysbiosis and disease severity in Parkinson's disease patients. Participants (52 patients and 117 healthy controls) provided stool samples for microbiota sequencing and urine samples for urolithin profiling before and after consuming 30 g of walnuts for three days. Data on demographics, medication, disease duration and Hoehn and Yahr disease stage were collected. We observed a significant gradual increase of urolithin non-producers (metabotype-0) as the disease severity increased. The gut microbiome of metabotype-0 patients and patients with the greatest severity was characterized by a more altered bacterial composition, i.e., increased pro-inflammatory Enterobacteriaceae and reduced protective bacteria against autoimmune and inflammatory processes, including butyrate and urolithin-producing bacteria (Lachnospiraceae members and Gordonibacter). Besides, their microbiome was characterized by predictive functions of lipopolysaccharide biosynthesis and metabolism of glutathione, cysteine and methionine that could indirectly reflect the gut pro-inflammatory status. Urolithin detection in urine is a feasible, non-invasive and fast approach that can reflect gut microbiome dysbiosis and intestinal inflammation in Parkinson's disease patients. Our current study could provide novel strategies for improving diagnostics, and for preventing and treating disease progression in microbiota-based interventions.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Juglans / Microbioma Gastrointestinal Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Food Funct Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Juglans / Microbioma Gastrointestinal Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Food Funct Año: 2022 Tipo del documento: Article País de afiliación: España